Extracellular domains of the β, γ and ε subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: A combination of immunoadsorbents results in increased efficiency

Journal of Neuroimmunology

Volumn 190, Issue 1-2, 2007, Pages 44-52

  Kostelidou, Kalliopi ^a   Trakas, Nikolaos ^a   Tzartos, Socrates J ^a,b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Acetylcholine receptor; Autoimmune diseases; Extracellular domain; Myasthenia gravis; Specific immunoadsorption; Therapy

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BETA; CHOLINERGIC RECEPTOR EPSILON; CHOLINERGIC RECEPTOR GAMMA; RECEPTOR SUBUNIT; SEPHAROSE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ARTICLE; BETA CHAIN; HUMAN; IMMUNOADSORBENT; MYASTHENIA GRAVIS; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

AUTOANTIBODIES; CELL LINE; DRUG COMBINATIONS; DRUG SYNERGISM; EXTRACELLULAR FLUID; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; IMMUNOTHERAPY; MYASTHENIA GRAVIS; PROTEIN STRUCTURE, TERTIARY; PROTEIN SUBUNITS; RECEPTORS, NICOTINIC;

EID: 35448949074     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.07.018     Document Type: Article

References (37)

1. Batocchi A.P., Evoli A., Dischino C., and Tonali P. Therapeutic apheresis in myasthenia gravis. Ther. Apher. 4 (2000) 275-279
2. Beeson D., Amar M., Bermudez I., and Vincent A. Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the epsilon subunit. Neurosci. Lett. 207 (1996) 57-60
3. Dalakas M.C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacology 33 (2004)
4. Fostieri E., Kostelidou K., Poulas K., and Tzartos S.J. Recent advances in the understanding and therapy of myasthenia gravis. Future Neurol. 1 (2006) 799-801
5. Geuder K.I., Marx A., Witzemann V., Schalke B., Toyka K., Kircher T., and Muller-Hermelink H.K. Pathogenetic significance of fetal-type acetylcholine receptors on thymic myoid cells in myasthenia gravis. Dev. Immunol. 2 (1992) 69-75
6. Heidenreich F., Vincent A., Willcox N., and Newsom-Davis J. Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology 38 (1988) 1784-1788
7. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
8. Jambou F., Zhang W., Menestrier M., Klingel-Schmitt I., Michel O., Caillat-Zucman S., Aissaoui A., Landemarre L., Berrih-Aknin S., and Cohen-Kaminsky S. Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis. J. Clin. Invest. 112 (2003) 265-274
9. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat. Rev., Neurosci. 3 (2002) 102-114
10. Keesey J.C. Clinical evaluation and management of myathenia gravis. Muscle Nerve 29 (2004) 484-505
11. Kostelidou K., Trakas N., Zouridakis M., Bitzopoulou K., Sotiriadis A., Gavra I., and Tzartos S.J. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor. FEBS J. 273 (2006) 3557-3568
12. Kuks J.B., and Skallebaek D. Plasmapheresis in myasthenia gravis: a survey. Transfus. Sci. 19 (1998) 129-136
13. Le Novere N., Corringer P.J., and Changeux J.P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J. Neurobiol. 53 (2002) 447-456
14. Lindstrom J.M., Engel A.G., Seybold M.E., Lennon V.A., and Lambert E.H. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144 (1976) 739-753
15. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
16. Lindstrom J., Einarson B., and Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74 (1981) 432-460
17. Luther M.A., Schoepfer R., Whiting P., Casey B., Blatt Y., Montal M.S., and Lindstrom J. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J. Neurosci. 9 (1989) 1082-1096
18. Matic G., Bosch T., and Ramlow W. Background and indications for protein-A based extracorporeal immunoadsorption. Ther. Apher. 5 (2001) 394-403
19. Navaneetham D., Penn A.S., Howard J.F., and Conti-Fine B.M. Human thymuses express incomplete sets of muscle acetylcholine receptor subunit transcripts that seldom include the δ subunit. Muscle Nerve 24 (2001) 203-210
20. Newsom-Davis J., Wilson S.G., Vincent A., and Ward C.D. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1 (1979) 464
21. Pinching A.J., and Peters D.K. Remission of myasthenia gravis following plasma-exchange. Lancet 2 (1976) 1373-1376
22. Psaridi-Linardaki L., Mamalaki A., Remoundos M., and Tzartos S.J. Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding. J. Biol. Chem. 277 (2002) 26980-26986
23. Psaridi-Linardaki L., Trakas N., Mamalaki A., and Tzartos S.J. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J. Neuroimmunol. 159 (2005) 183-191
24. Ptak J. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis. Transfus. Apher. Sci. 30 (2004) 125-129
25. Ragheb S., and Lisak R.P. Differences between the ε and γ subunits of the acetylcholine receptor (AChR) may be significant in the autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 998 (2003) 336-338
26. Richman D.P., and Agius M.A. Treatment of autoimmune myasthenia gravis. Neurology 61 (2003) 1652-1661
27. Sieb J.P. Myasthenia gravis: emerging new therapy options. Curr. Opin. Pharmacol. 5 (2005) 303-307
28. Skeie G.O., Apostolski S., Evoli A., Gilhus N.E., Hart I.K., Harms L., Hilton-Jones D., Melms A., Verschuuren J., and Horgel H.W. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 13 (2006) 691-699
29. Takamori M., and Maruta T. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Ther. Apher. 5 (2001) 340-350
30. Tzartos S.J., and Lindstrom J.M. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 755-759
31. Tzartos S.J., Seybold M.E., and Lindstrom J.M. Specificities of antibodies to acetylcholine receptors in sera from myasthenic gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 188-191
32. Tzartos S.J., Kokla A., Walgrave S.L., and Conti-Tronconi B.M. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 2899-2903
33. Tzartos S.J., Barkas T., Cung M.T., Mamalaki A., Marraud M., Orlewski P., Papanastasiou D., Sakarellos C., Sakarellos-Daitsiotis M., Tsantili P., and Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163 (1998) 89-120
34. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4 ? resolution. J. Mol. Biol. 346 (2005) 967-989
35. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev., Immunol. 2 (2002) 797-804
36. Vincent A., Palace J., and Hilton-Jones D. Myasthenia gravis. Lancet 357 (2001) 2122-2128
37. Yamazaki Z., Fujimori Y., Takahama T., Inoue N., Wada T., Kazama M., Morioka M., Abe T., Yamawaki N., and Inagaki K. Efficiency and biocompatibility of a new immunosorbent. Trans. Am. Soc. Artif. Intern. Organs 28 (1982) 318-323